Nuggets overweight/obesity drug market GLP-1 receptor agonists do their part

With the rapid economic development, the number of overweight/obese people is increasing due to multiple factors such as changes in dietary structure, living environment and habits of Chinese residents.

It should be noted that the diagnostic criteria for overweight and obesity are different

Overweight and obesity have a collective cause serious consequences, such as cardiovascular disease, diabetes, musculoskeletal disorders and endometrial cancer, breast cancer, colon cancer and so on

According to the Insight database, there are limited domestic drugs approved for overweight and obesity, including fenfluramine, mazindole, sibutramine, lorcaserin and orlistat

Glucagon-like peptide-1 (GLP-1) receptor agonists are a new class of hypoglycemic drugs that have been on the market in recent years

At present, a variety of GLP-1 receptor agonists in China have been developed for overweight/obesity.

IBI-362 (OXM3) is a natural peptide analog derived from the post-transcriptional processing of the preglucagon gene in the intestine

BI456906 is derived from the natural intestinal hormone oxyntomodulin, which can activate GLP-1 and glucagon receptor (GCG), which are essential for controlling metabolic functions.

Cagrilintide is an amylin analogue under development by Novo Nordisk.

PB-119 is modified by PEGylation on the basis of Exenatide, which can prolong the half-life of the drug, and finally achieve once a week subcutaneous injection to control the blood sugar level steadily and effectively

TG103 is an innovative long-acting recombinant human GLP-1 Fc fusion protein

Moreover, in order to accelerate the development of these GLP-1R agonists, domestic and foreign pharmaceutical companies have reached several cooperations